Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug.  

For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer return.  

Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma, but tazemetostat is not approved for patients with this cancer. 

Researchers at The Institute of Cancer Research (ICR), London, worked as part of the SPECIFICANCER team funded by Cancer Research UK and the Mark Foundation for Cancer Research. 

The SPECIFICANCER team have previously shown that drugs such as tazemetostat can be more effective for other hard-to-treat cancers such as triple-negative breast cancer and colorectal cancer, when used in combination with other drugs. 

DOT1L interacts with tazemetostat

The researchers at the ICR first knocked out genes in B-cell lymphoma cells, in the presence and absence of tazemetostat, and found that DOT1L is needed to interact with the drug to block cell growth. 

They discovered that combining tazemetostat with a DOT1L inhibitor drug called pinometostat, that is already in clinical trials, can shrink follicular lymphoma tumours in the lab that have developed resistance to tazemetostat. 

In mice, the drug combination significantly blocked DLBCL tumour growth, with no major side effects. After 15 days, tumours left to grow on their own had tripled in size and those treated with tazemetostat alone had also almost reached this size.  

Those treated with the DOT1L inhibitor alone had almost doubled, whilst those treated with the drug combination had shrunk. 

Tazemetostat targets EZH2 – an enzyme that is overexpressed and hyperactive in several cancers, including B-cell lymphoma, melanoma and prostate cancer.  

EZH2 inhibitors on their own have had mixed results in clinical trials – including in those for B cell lymphoma. 

Dr Van Nguyen, Postdoctoral Training Fellow at ICR, London, and study co-author, said: “Tazemetostat is a promising drug but unfortunately, many patients’ cancers either do not respond or they start growing again quickly. It’s exciting to see that combining it with a DOT1L inhibitor could allow thousands more people to benefit from the treatment.”

Diana Spencer, Senior Digital Content Editor, DDW